Literature DB >> 12871322

The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.

S He1, M Blombäck, G Jacobsson Ekman, U Hedner.   

Abstract

Patients with hemophilia have an impaired thrombin generation and therefore form loose fibrin hemostatic plugs that are easily dissolved by fibrinolysis. This prevents maintained hemostasis in these patients, resulting in a severe bleeding disorder. Recombinant (F)VIIa has been shown to enhance thrombin generation on already thrombin-activated platelets in the absence of FVIII and FIX. An efficacy rate of 80-90% has been found in hemophilia patients with inhibitors against FVIII or FIX both in association with major surgery and in the treatment of serious bleedings. In a model measuring fibrin clot permeability in a platelet-containing system described by Blombäck et al. (1994) this was demonstrated to be dependent on the concentration of FVIII and FIX. The addition of rFVIIa in concentrations of 1.9, 4.8 and 9.6 microg mL(-1) normalized fibrin clot permeability. The concentration of 1.9 microg mL(-1) of rFVIIa normalized clot permeability in this system and the higher concentrations of rFVIIa added only slightly to the effect. No further decrease in clot permeability was found when rFVIIa in a concentration of 1.9 microg mL(-1) was added to a sample with a normal concentration (100%) of FVIII or FIX. Higher concentrations of rFVIIa added to the plasma containing 100% of FVIII or FIX induced only a slight further decrease of fibrin permeability constant, arguing against any unwanted effect of extra rFVIIa on clot permeability in the case of a normal hemostasis. Furthermore, the fibrin network was studied with 3D microscopy and the loose network found in the absence of FVIII or FIX increased in density with increasing FVIII or FIX concentrations. The addition of rFVIIa to FVIII- or FIX-deficient systems altered the network structure, making the fibers thinner and more tightly packed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871322     DOI: 10.1046/j.1538-7836.2003.00242.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  26 in total

Review 1.  The use of recombinant activated coagulation factor VII for spine surgery.

Authors:  Richard B Weiskopf
Journal:  Eur Spine J       Date:  2004-05-25       Impact factor: 3.134

2.  The influence of coagulation and inflammation research on the improvement of polytrauma care.

Authors:  M Perl; M Huber-Lang; F Gebhard
Journal:  Eur J Trauma Emerg Surg       Date:  2011-11-09       Impact factor: 3.693

3.  Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.

Authors:  J D Beckman; L A Holle; A S Wolberg
Journal:  J Thromb Haemost       Date:  2017-11-20       Impact factor: 5.824

4.  Nanoparticle diffusion measures bulk clot permeability.

Authors:  Richard Chasen Spero; Rachel K Sircar; Ryan Schubert; Russell M Taylor; Alisa S Wolberg; Richard Superfine
Journal:  Biophys J       Date:  2011-08-17       Impact factor: 4.033

5.  Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.

Authors:  Laura D Gray; Michael A Hussey; Brittany M Larson; Kellie R Machlus; Robert A Campbell; Gary Koch; Mirella Ezban; Ulla Hedner; Alisa S Wolberg
Journal:  Thromb Res       Date:  2011-05-10       Impact factor: 3.944

6.  Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.

Authors:  R Stagaard; M J Flick; B Bojko; K Goryński; P Z Goryńska; C D Ley; L H Olsen; T Knudsen
Journal:  J Thromb Haemost       Date:  2018-06-21       Impact factor: 5.824

7.  Smoking out the cause of thrombosis.

Authors:  Robert A Campbell; Kellie R Machlus; Alisa S Wolberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01       Impact factor: 8.311

8.  Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

Authors:  Rikke Stagaard; Carsten Dan Ley; Kasper Almholt; Lisbeth Høier Olsen; Tom Knudsen; Matthew J Flick
Journal:  Blood Adv       Date:  2018-11-27

Review 9.  Thrombin generation, fibrin clot formation and hemostasis.

Authors:  Alisa S Wolberg; Robert A Campbell
Journal:  Transfus Apher Sci       Date:  2008-02-20       Impact factor: 1.764

10.  Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.

Authors:  Jun Zhang; Robert F Groff; Xiao-Han Chen; Kevin D Browne; Jason Huang; Eric D Schwartz; David F Meaney; Victoria E Johnson; Sherman C Stein; Rasmus Rojkjaer; Douglas H Smith
Journal:  Exp Neurol       Date:  2008-01-05       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.